USRE47214E1 - 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates - Google Patents

4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates Download PDF

Info

Publication number
USRE47214E1
USRE47214E1 US15/616,347 US201115616347A USRE47214E US RE47214 E1 USRE47214 E1 US RE47214E1 US 201115616347 A US201115616347 A US 201115616347A US RE47214 E USRE47214 E US RE47214E
Authority
US
United States
Prior art keywords
methyl
phase
pyrazol
oxy
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/616,347
Other languages
English (en)
Inventor
Ramón Berenguer Maimó
Jorge Medrano Rupérez
Jordi Benet Buchholz
Laura Puig Fernandez
Laia Pellejà Puxeu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10382025A external-priority patent/EP2361904A1/en
Priority claimed from EP10382226A external-priority patent/EP2426112A1/en
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to US15/616,347 priority Critical patent/USRE47214E1/en
Assigned to LABORATORIOS DEL DR. ESTEVE, S.A. reassignment LABORATORIOS DEL DR. ESTEVE, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDRANO RUPÉREZ, Jorge, BENET BUCHHOLZ, JORDI, Berenguer Maimó, Ramón , PELLEJÀ PUXEU, Laia, PUIG FERNANDEZ, LAURA
Application granted granted Critical
Publication of USRE47214E1 publication Critical patent/USRE47214E1/en
Assigned to ESTEVE PHARMACEUTICALS, S.A. reassignment ESTEVE PHARMACEUTICALS, S.A. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: LABORATORIOS DEL DR. ESTEVE S.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to polymorphs and solvates of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027), processes for their preparation, and to pharmaceutical compositions comprising them.
  • sigma receptor a cell surface receptor of the central nervous system (CNS) which may be related to the dysphoric, hallucinogenic and cardiac stimulant effects of opioids.
  • CNS central nervous system
  • sigma receptor ligands may be useful in the treatment of psychosis and movement disorders such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington's chorea or Tourette's syndrome and in Parkinson's disease (Walker, J. M. et al, Pharmacological Reviews, 1990, 42, 355).
  • the sigma receptor has at least two subtypes, which may be discriminated by stereoselective isomers of these pharmacoactive drugs.
  • SKF 10047 has nanomolar affinity for the sigma 1 ( ⁇ -1) site, and has micromolar affinity for the sigma 2 ( ⁇ -2) site.
  • Haloperidol has similar affinities for both subtypes.
  • Endogenous sigma ligands are not known, although progesterone has been suggested to be one of them.
  • Possible sigma-site-mediated drug effects include modulation of glutamate receptor function, neurotransmitter response, neuroprotection, behavior, and cognition (Quirion, R. et al. Trends Pharmacol. Sci., 1992, 13:85-86).
  • sigma binding sites are plasmalemmal elements of the signal transduction cascade. Drugs reported to be selective sigma ligands have been evaluated as antipsychotics (Hanner, M. et al. Proc. Natl. Acad. Sci., 1996, 93:8072-8077). The existence of sigma receptors in the CNS, immune and endocrine systems have suggested a likelihood that it may serve as link between the three systems.
  • 4-[2-[([5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine is a highly selective sigma-1 ( ⁇ -1) receptor antagonist. It has displayed strong analgesic activity in the treatment and prevention of chronic and acute pain, and particularly, neuropathic pain.
  • the compound has a molecular weight 337.42 uma.
  • the structural formula of the compound is:
  • the solid state physical properties of a pharmaceutical compound can be influenced by the conditions under which the compound is obtained in solid form.
  • Solid state physical properties include, for example, the flowability of the milled solid which affects the ease with which the compound is handled during processing into a pharmaceutical product.
  • Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid. The rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences because it imposes an upper limit on the rate at which an orally administered active ingredient can reach the blood.
  • the solid-state form of a compound may also affect its solubility, bioavailability, behavior on compaction, stability, or its electrostatic nature.
  • Polymorphism is the property of some molecules and molecular complexes to assume more than one crystalline or amorphous form in the solid state.
  • polymorphism is caused by the ability of the molecule of a substance to change its conformation or to form different inter molecular and intramolecular interactions, particularly hydrogen bonds, which is reflected in different atom arrangements in the crystal lattices of different polymorphs. Accordingly, polymorphs are distinct solids sharing the same molecular Formula, having distinct advantageous and/or disadvantageous physical properties compared to other forms in the polymorph family.
  • solvate refers to any solid form of a given compound in which said compound is bonded by a non-covalent bond to molecule(s) of solvent (normally a polar solvent).
  • new solid forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine may achieve one or more of the above mentioned objectives.
  • the novel polymorphic and solvated forms of P027 herein disclosed are fairly stable over the time and have good flow and dissolution characteristics.
  • a novel and highly stable crystalline form of the P027 compound provides advantageous production, handling, storage and therapeutic properties.
  • some of the new solid forms of P027 may be useful as intermediates for other useful forms such as the crystalline phase I form of P027.
  • the present invention relates to polymorphic forms and solvates of P027, to their use and to several processes for their preparation.
  • the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine can be prepared by contacting a solution of the base with hydrochloric acid.
  • the P027 compound has a molecular weight 373.88 uma, a pKa of 6.73 and a melting point of 194.2° C.
  • the compound is very soluble in water and freely soluble in methanol, 1N hydrochloric acid and dimethyl sulphoxide. It is sparingly soluble in ethanol, slightly soluble in acetone and practically insoluble in ethyl acetate and in 1N sodium hydroxide.
  • the product exhibits a better dissolution and absorption profile in vivo than its related base.
  • the present invention is directed to a solid polymorphic or solvated form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine.
  • said solid form is selected from the group consisting of:
  • the crystalline P027 phase I form of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride according to the present invention has a monoclinic unit cell with the following approximate dimensions:
  • the P027 phase I form can be prepared by crystallizing the P027 compound in various solvents by means of various techniques such as: solvent evaporation at varying temperatures, crystallization from hot saturated solutions, crystallization by antisolvent addition, crystallization by antisolvent diffusion, crystallization from water and solvents mixtures and the preparation of suspensions.
  • P027 phase II form may be obtained in polymer induced crystallizations by solvent evaporation.
  • P027 phase III form may be obtained in polymer induced crystallizations either by solvent evaporation or by crystallization by antisolvent addition.
  • P027 phase IV form may be obtained in polymer induced crystallizations by crystallization by antisolvent addition.
  • P027 dioxane solvate may be obtained by solvent drop grinding in dioxane or by crystallization from a hot saturated solution of dioxane.
  • P027 chloroform solvate may be obtained in polymer induced crystallizations either by solvent (chloroform) evaporation or by crystallization from hot saturated solutions of chloroform.
  • Another embodiment of the present invention includes the transformation of crystalline forms phase II, phase III and phase IV above into a more stable polymorphic form such as P027 phase I form.
  • Another embodiment of the present invention includes the transformation of a solvate of P027, preferably chloroform solvate, into a more stable polymorphic form such as phase I form.
  • a further embodiment of the present invention includes pharmaceutical compositions comprising at least one of the forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine above-mentioned, particularly P027 phase I, P027 phase II. P027 phase III. P027 phase IV. P027 chloroform solvate and P027 dioxane solvate.
  • FIG. 1 Standard PXRD pattern of phase I.
  • FIG. 2 1 H NMR spectrum of a P027 compound solution.
  • FIG. 3 DSC and TGA analyses of phase I.
  • FIG. 4 FTIR analysis of phase I.
  • FIG. 5 Randomly selected PXRD patterns of different solids corresponding to phase I in which texture effects can be observed.
  • FIG. 6 PXRD pattern of phase I samples before and after grinding. The standard PXRD pattern of phase I is shown for comparison purposes.
  • FIG. 7 1 H-NMR spectra of the samples depicted in FIG. 6 .
  • FIG. 8 DSC analysis of phase I at a heating rate of 5° C./min.
  • FIG. 9 DSC analysis of phase I at a heating rate of 20° C./min.
  • FIG. 10 Ortep-Plot (50%) showing the organic cation and the two independent half chlorine anions contained in the unit cell.
  • FIG. 11 Ortep-Plot (50%) showing the structure of phase I. The hydrogen bonds are marked with discontinuous lines.
  • FIG. 12 Simulated powder diffraction pattern generated from the single crystal data of phase I.
  • FIG. 13 Comparison of the simulated powder diffraction pattern obtained from single crystal data and the experimentally measured powder diffraction pattern of phase I.
  • FIG. 14 PXRD pattern of a phase I form obtained by the evaporation n-butanol at ⁇ 21° C.
  • FIG. 15 PXRD pattern of a phase I form obtained by the slow crystallization of hot saturated P027 compound solution in methyl ethyl ketone.
  • FIG. 16 PXRD pattern of a phase I form obtained by crystallization through the addition of a P027 solution in methanol to an n-heptane solution.
  • FIG. 17 PXRD pattern of a phase I form obtained by crystallization through a liquid-liquid diffusion of a P027 solution in nitromethane and an isopropyl ether solution.
  • FIG. 18 PXRD pattern obtained after grinding a sample of P027 phase I form together with dichloromethane. The pattern is consistent with the standard phase I PXRD pattern demonstrating the phase stability.
  • FIG. 19 PXRD pattern of a sample of P027 phase I form after applying a pressure of 30 tons to the sample for 90 minutes. The pattern is consistent with the standard phase I PXRD pattern demonstrating the phase stability.
  • FIG. 20 Comparison of the PXRD patterns obtained for Phase II and Phase III.
  • FIG. 21 Comparison of the PXRD patterns obtained for Phase II and Phase IV.
  • FIG. 22 Comparison of the PXRD patterns obtained for Phase III and Phase IV.
  • FIG. 23 Comparison of the PXRD patterns obtained for Phase I and Phase II.
  • FIG. 24 Standard PXRD pattern of Phase II.
  • FIG. 25 1 H NMR spectrum of Phase II.
  • FIG. 26 DSC and TGA analyses of Phase II.
  • FIG. 27 Standard PXRD pattern of Phase III.
  • FIG. 28 Comparison of the PXRD patterns obtained for poly(ethylene glycol) and Phase III.
  • FIG. 29 1 H NMR spectrum of Phase III.
  • FIG. 30 1 H NMR spectrum of poly(ethylene glycol).
  • FIG. 31 DSC and TGA analyses of Phase III.
  • FIG. 32 DSC and TGA analyses of poly(ethylene glycol).
  • FIG. 33 DSC analyses of Phase III with a heating rate of 20° C./min.
  • FIG. 34 DSC analyses of Phase III with a heating rate of 30° C./min.
  • FIG. 35 Standard PXRD pattern of Phase IV.
  • FIG. 36 1 H NMR spectrum of Phase IV.
  • FIG. 37 DSC and TGA analyses of Phase IV.
  • FIG. 38 Standard PXRD pattern of the dioxane solvate.
  • FIG. 39 NMR spectrum of the dioxane solvate.
  • FIG. 40 DSC and TGA analyses of the dioxane solvate.
  • FIG. 41 FTIR analysis of the dioxane solvate.
  • FIG. 42 Standard PXRD pattern of the chloroform solvate.
  • FIG. 43 DSC and TGA analyses of the chloroform solvate.
  • novel solid forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) which provide advantageous production, handling, storage and therapeutic properties.
  • These compounds have advantages due to the fact that they are solids, what simplifies isolation, purification and handling.
  • the phase I form of this compound is highly stable and can be formulated and administered providing stable compositions and good pharmacological properties.
  • the new forms of P027 may be used for obtaining other forms, such as crystalline phase I form of P027.
  • the term “about” means a slight variation of the value specified, preferably within 10 percent of the value specified. Nevertheless, the term “about” can mean a higher tolerance of variation depending on for instance the experimental technique used. Said variations of a specified value are understood by the skilled person and are within the context of the present invention. Further, to provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”.
  • room temperature or its abbreviation “rt” is taken to mean 20 to 25° C.
  • the new forms of P027 herein disclosed were characterized by powder X-ray diffraction (PXRD), proton nuclear magnetic resonance ( 1 H-NMR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and Fourier-transformed infrared spectroscopy.
  • PXRD powder X-ray diffraction
  • 1 H-NMR proton nuclear magnetic resonance
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Fourier-transformed infrared spectroscopy The present invention is directed in one aspect to the new solid forms of P027 in themselves, regardless of the technique used for their characterization. Therefore, the techniques and results provided herein are not intended to limit the present invention, but to serve as characterization of the same.
  • solubility of P027 was determined at room temperature in the set of solvents of table 6 using the following methodology (table 7): 10 mg of the delivered sample were suspended at room temperature in 0.2 mL of the corresponding solvent and successive additions (initially 0.2 mL and finally 0.5 mL) of solvent until the solid was completely dissolved or up to a maximum of 8 mL were performed. After each solvent addition the suspension was vigorously stirred for 10-15 minutes and visually inspected to determine if the solid was completely dissolved. Solubility ranges are listed in table 7.
  • the solvents in which P027 was insoluble were used as antisolvents (e.g. those solvents providing a solubility ⁇ 1.2 mg/mL).
  • antisolvents e.g. those solvents providing a solubility ⁇ 1.2 mg/mL.
  • HEP n-Heptane
  • MTE Methyl tert-butyl ether
  • DIE diisopropyl ether
  • the other solvents were used as dissolving solvents in the different crystallization strategies assayed.
  • catalytic amounts represent a substoichiometric amount of polymer with respect to the compound P027; preferably below a 25% wt of the amount (wt) of compound P027: In a particular embodiment, “catalytic amounts” represent below a 20% wt of the compound P027. In a more particular embodiment, “catalytic amounts” represent below a 10% wt of the compound P027.
  • P027 phase I form P027 phase II form
  • P027 phase III form P027 phase IV form
  • P027 dioxane solvate P027 chloroform solvate.
  • the P027 phase I form is obtained by dissolving the P027 compound in a suitable solvent and then evaporating the solvent to obtain the phase I crystalline form.
  • the P027 compound is dissolved at a temperature ranging from about room temperature to about 120° C.
  • the solvent is evaporated at a temperature ranging from about ⁇ 21° C. to about 60° C.
  • the P027 solution is allowed to cool down slowly.
  • the P027 solution is cooled down rapidly.
  • the P027 phase I form is obtained by mixing a P027 solution and an antisolvent.
  • the P027 solution is added to the anti solvent.
  • the antisolvent is added to the P027 solution.
  • the P027 solution and the antisolvent are mixed at a temperature ranging from about room temperature to about 90° C.
  • the P027 phase I form is obtained by combining a P027 solution and an antisolvent through diffusion.
  • the diffusion is a liquid-liquid diffusion.
  • the diffusion is a gas-liquid diffusion.
  • the P027 phase I form is collected from mixtures of P027, water and solvents.
  • the P027 phase I form is obtained from suspensions containing the P027 compound.
  • the suspension is maintained at a temperature ranging from about room temperature to about 80° C.
  • an hydrochloric acid solution and 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine are mixed to obtain the P027 compound.
  • an antisolvent is added to the mixture to induce the crystallization of the P027 compound.
  • phase II form, phase III form and phase IV form may be obtained in polymer induced crystallizations either by solvent evaporation or by crystallization by antisolvent addition.
  • another embodiment of the present invention refers to a process for the preparation of polymorphic forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine, comprising:
  • P027 phase II form is prepared by evaporation of a solution of P027 in water with the presence of catalytic amounts of poly(vinyl alcohol).
  • P027 phase III form is prepared by evaporation of a solution of P027 in water or acetone with the presence of catalytic amounts of poly(ethylene glycol).
  • P027 phase III form may also be conveniently prepared by addition of diisopropyl ether as antisolvent to a solution of P027 in water with the presence of catalytic amounts of poly(ethylene glycol).
  • P027 phase IV form is prepared by using chloroform as solvent, diisopropyl ether as antisolvent and the following polymers: polyvinyl pyrrolidone (PVP), poly(acrylic acid) (PAA), polypropylene (PPL), poly(styrene-co-divinylbenzene) (PSV), poly(tetrafluoroethylene) (PTF), poly(vinyl alcohol) (PVH), polyacrylamide (PAD) and poly(methyl methacrilate methacrylate) (PMM).
  • PVP polyvinyl pyrrolidone
  • PAA poly(acrylic acid)
  • PPL polypropylene
  • PSV poly(styrene-co-divinylbenzene)
  • PTF poly(tetrafluoroethylene)
  • PVH poly(vinyl alcohol)
  • PAD polyacrylamide
  • PMM poly(methyl methacrilate methacrylate)
  • P027 dioxane solvate may be obtained in a solvent drop grinding experiment in dioxane or by crystallization from a hot saturated solution of dioxane.
  • P027 chloroform solvate may be obtained in polymer induced crystallizations either by solvent (chloroform) evaporation or by crystallization of hot saturated solutions of chloroform.
  • another embodiment of the present invention refers to a process for the preparation of solvated forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine, comprising at least one of the 3 alternatives i) to iii):
  • P027 dioxane solvate is prepared by:
  • P027 chloroform solvate is prepared by:
  • Another embodiment of the present invention includes the use of crystalline forms phase II, phase III and phase IV of P027 in the obtention of the more stable polymorphic phase I form of P027.
  • the transformation is by heating of crystalline forms phase II, phase III and phase IV into the polymorphic phase I form.
  • phase II In the DSC analysis of phases II, III and IV broad exothermic peaks were observed which correspond to a solid-solid transition.
  • the solid-solid transition (recrystallization) of phase II to phase I was observed at 145° C.
  • the solid-solid transition (recrystallization) of phase III into phase I was observed in the range 150-170° C.
  • the solid-solid transition (recrystallization) of phase IV into phase I was observed at 147° C.
  • the invention is directed to the preparation of phase I form of P027 comprising the step of heating crystalline forms phase II, phase III and phase IV of P027 at a temperature between about 140° C. and about 170° C.
  • Another embodiment of the present invention includes the transformation of a solvate of P027, preferably chloroform solvate, into a more stable polymorphic form such as phase I form. After drying the dioxane solvate for 4 hours at 60° C., 80° C. and 100° C. the transformation to Phase I was observed. The solids obtained were characterized by PXRD.
  • a further embodiment of the present invention includes pharmaceutical compositions comprising at least one of the forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine above-mentioned, particularly P027 phase I, P027 phase II, P027 phase III, P027 phase IV, P027 chloroform solvate and P027 dioxane solvate,
  • Powder diffraction patterns were acquired on a D8 Advance Series 2Theta/Theta powder diffraction system using Cu K ⁇ -radiation in transmission geometry (Wavelength: 1.54060).
  • the system was equipped with a V ⁇ hacek over (A) ⁇ NTEC-1 single photon counting PSD, a Germanium monochromator, a ninety positions auto changer sample stage, fixed divergene slits and radial soller.
  • Standard DSC analyses were recorded in a Mettler Toledo DSC822e. Samples of 1-2 mg were weighted into 40 ⁇ L aluminium crucibles with a pinhole lid, and were heated, under nitrogen (50 mL/min), from 30 to 300° C. at 10° C./min. Data collection and evaluation was done with software STARe.
  • Thermogravimetric analyses were recorded in a Mettler Toledo SDTA851e. Samples of 3-4 mg were weighted (using a microscale MX5, Mettler) into open 40 ⁇ L aluminium crucibles with a pinhole lid, and heated at 10° C./min between 30 and 500° C., under nitrogen (80 mL/min). Data collection and evaluation was done with software STARe.
  • the FTIR spectra were recorded using a Bruker Tensor 27, equipped with a MKII golden gate single reflection ATR system, a mid-infrared source as the excitation source and a DTGS detector.
  • the spectra were acquired in 32 scans at a resolution of 4 cm ⁇ 1 . No sample preparation was required to perform the analysis.
  • Crystal structure solution was achieved using direct methods as implemented in SHELXTL Version 6.10 (Sheldrick, Universttician Göttingen (Germany), 2000) and visualized using XP program. Missing atoms were subsequently located from difference Fourier synthesis and added to the atom list. Least-squares refinement on F 0 2 using all measured intensities was carried out using the program SHELXTL Version 6.10 (Sheldrick, Universttician Göttingen (Germany), 2000). All non hydrogen atoms were refined including anisotropic displacement parameters.
  • FIG. 14 illustrates the PXRD pattern of a phase I form obtained by the evaporation of a n-butanol solution at ⁇ 21° C. according to the present protocol.
  • the solids obtained were separated by filtration or centrifugation. If no solids were formed, the solution was kept at 4° C. for a few days in first step. Any solids formed during this step were separated from the solution. If no solids were formed during the first step, the solution was kept at ⁇ 21° C. for a few additional days. Any solids formed during this second step were separated from the solution. The solutions that did not crystallize during the second step were left to evaporate to dryness at room temperature. The solid was filtered off in some experiments when crystallization occurred before complete evaporation.
  • FIG. 15 illustrates the PXRD pattern of a phase I form obtained by the slow crystallization of hot saturated P027 compound solution in methyl ethyl ketone.
  • DIE Diisopropyl ether
  • HEP n-heptane
  • the solids obtained after mixing the dissolving agent and antisolvent were separated from the solution by filtration or centrifugation. If no solids were formed, the solution was kept at 4° C. for a few days in first step. Any solids formed during this step were separated from the solution. If no solids were formed during the first step, the solution was kept at ⁇ 21° C. for a few additional days. Any solids formed during this second step were separated from the solution. The solutions that did not crystallize during the second step were left to evaporate to dryness at room temperature. The solid was filtered off in some experiments when crystallization occurred before complete evaporation.
  • FIG. 16 illustrates the PXRD pattern of a phase I form obtained by crystallization through the addition of a P027 solution in methanol to an n-heptane solution.
  • FIG. 17 illustrates the PXRD pattern of a phase I form obtained by crystallization through a liquid-liquid diffusion of isopropyl ether into a P027 solution in nitromethane.
  • the solutions were allowed to crystallize at room temperature in a closed tube for two weeks. If no solids were formed, the solution was kept at 4° C. for a few days. Any solids formed during this step were separated from the solution. If no solids were formed during the first step, the solution was left to evaporate to dryness at room temperature.
  • the solid samples obtained were analyzed by PXRD.
  • the samples showed a pattern consistent with the standard PXRD phase I pattern.
  • P027 phase I Approximately 40 mg of P027 phase I were transferred to a ball mill container together with catalytic quantities of the relevant solvent (three drops). The P027 phase I and the solvent were grinded at a maximum frequency of 30 s ⁇ 1 for 30 minutes (see Table 23).
  • FIG. 18 illustrates the PXRD pattern of a phase I form obtained from grinding P027 together with dichloromethane.
  • Tablets of P027 phase I were prepared in a hydraulic press at three different pressures (5, 7.5 and 10 tons) for three different times (5, 30 and 90 minutes) [see Table 24].
  • FIG. 19 illustrates the PXRD pattern of a phase I form obtained by applying a pressure of 30 tons to P027 for 90 minutes.
  • the P027 phase I form shows a PXRD pattern having characteristic peaks at a reflection angle [2 ⁇ ] of about 5.9, 8.1, 11.3, 11.7, 14.2, 15.1, 15.8, 16.3, 16.8, 17.8, 18.1, 18.6, 19.8, 20.9, 21.9, 22.8, 23.0, 23.2, 23.6, 23.9, 24.3, 25.0, 25.1, 28.0, 28.3, 28.6, 29.0, 29.2, 30.7, and 30.9 with the 2 ⁇ values being obtained using copper radiation (Cu K ⁇ 1 1.54060 ⁇ ).
  • Differences in the PXRD patterns peak intensities could be observed depending of the crystallization procedure or crystallization solvent used (see FIG. 5 ). Strong differences in the peak intensities could be due to preferred orientations, texture effects, of the crystals and are not indicative of the presence of different crystalline phases. Non ideal crystalline phases are defined by the peak positions and not by the peak intensities. Differences in the peak intensities could be due to different configurations of the measurement devices (transmission vs. reflection) or to texture effects related to the preferred orientations of the crystals.
  • phase I was analyzed by 1 H NMR in order to check the stability of the salt.
  • the chemical shifts and the integrations of the 1 H NMR signals were coincident for all samples and no signs of the lost of HCl or decomposition of the samples could be observed (see FIG. 7 ).
  • a DSC analysis of phase I samples was performed with a heating rate of 10° C./min.
  • the analysis presented a sharp endothermic peak, which does not recover the base line, with an onset at 194° C. and an enthalpy of 103 J/g corresponding to melting followed by decomposition of the product (see FIG. 3 ).
  • additional DSC analyses of the same sample performed with a heating rate of 5° C./min and 20° C./min, it was observed that the onset temperature of the endothermic peak does not vary with the heating rate (see FIGS. 8 and 9 ).
  • the FTIR spectrum of P027 phase I presented intense peaks at about 2965, 2609, 1632, 1600, 1559, 1508, 1490, 1439, 1376, 1301, 1257, 1242, 1169, 1129, 1103, 1042, 1010, 932, 914, 862, 828 and 753 cm ⁇ 1 (see FIG. 4 ).
  • the identity and crystal structure of the P027 compound phase I was assayed by a single crystal X-ray structure determination. Suitable crystals were obtained by slow diffusion of n-heptane into a concentrated solution of the product in acetone. Since the selected crystals were mostly twinned, a small fragment of a plate (0.30 ⁇ 0.30 ⁇ 0.07 mm 3 ) was separated with a micro scalpel and used for single crystal X-ray structure determination. Table 26 shows the measurement conditions utilized, cell constants and results obtained in a single crystal X-ray structure diffraction analysis. Table 27 depicts phase I selected bond distances and angles for an X-ray structure determination performed at 100 K.
  • Each cationic molecule shares two chlorine anions with neighboring cationic molecules.
  • One of the shared chlorine atoms is linked to the positively charged N—H-groups of two neighboring cationic molecules making two hydrogen bonds (C11 . . . N3-distance: 3.13 ⁇ ) [see FIGS. 10 and 11 ].
  • the second shared chlorine anion is located in the intermolecular space making only weak interactions to the surrounding molecules (shortest distance is C12 . . . C17-distance: 3.56 ⁇ ).
  • the powder diffraction pattern simulated from the single crystal data shows a good correspondence to the experimentally measured standard powder diffraction pattern of phase I.
  • the overlay confirms the phase purity. Small variations in peak positions are due to the temperature difference at which the compared powder diffractograms were measured (simulated at ⁇ 173° C. and experimentally measured at room temperature).
  • FIGS. 12 and 13 show the phase I simulated powder diffraction pattern and its comparison to the experimentally measured pattern, respectively.
  • phase II a mixture of phase I and a phase II was obtained by solvent evaporation in several solvents (methanol, water, diisopropyl ether-water, nitromethane dioxane-water and heptane-water).
  • solvents methanol, water, diisopropyl ether-water, nitromethane dioxane-water and heptane-water.
  • This new phase II could be reproduced pure in the screening performed using polymers by evaporation of a solution of P027 in water and with the presence of catalytic amounts of poly(vinyl alcohol).
  • phase II obtained using poly(vinyl alcohol) is pure and no peaks of phase I can be detected in the pattern.
  • a standard PXRD pattern for phase II form is shown in FIG. 24 .
  • FIGS. 25 and 26 Characterization by 1 H NMR, DSC and TGA is shown in FIGS. 25 and 26 .
  • the 1 H NMR spectrum obtained from the mixture of phases I and II is identical to the one obtained for phase I indicating that phase II is not a decomposition product.
  • the spectra obtained for phase I and phase II are compared in FIG. 25 . No differences in the shifts of relevant hydrogen atoms can be observed.
  • the DSC analysis of phase II shows a weak broad exothermic peak with an onset at 145° C. and an enthalpy of 4 J/g and a sharp endothermic peak with an onset at 194° C. and an enthalpy of 92 J/g, corresponding to melting followed by decomposition of the product ( FIG. 26 ).
  • the small exothermic peak at 145° C. suggests that phase II should be a metastable phase monotropically related to phase I.
  • the DSC actually shows a solid-solid transition of phase II to I, followed by fusion of phase I.
  • phase II In the TG analysis of phase II ( FIG. 26 ) a weight loss, due to decomposition of the sample, is observed at temperatures higher than 195° C. The starting temperature of weight loss in the TGA coincides with the melting temperature, confirming that the sample decomposes on melting. No weight loss is observed at temperatures below 180° C., indicating the absence of solvent.
  • the TG analysis of the solid containing phase II is identical to the one obtained for phase I.
  • Phase III form was generated by polymer induced crystallization. This solid was obtained in four experiments always in the presence of poly(ethylene glycol). In three cases it was obtained by evaporation of water or acetone and in one case it was obtained by addition of diisopropyl ether as antisolvent to a solution in water.
  • Phase III was characterized by PXRD, 1 H NMR, DSC and TGA.
  • a representative PXRD pattern for phase III is shown in FIG. 27 .
  • the peak at 19.1° in 2 ⁇ can be observed as a weak signal and the broad peak at 23.2° in 2 ⁇ can be also observed slightly shifted to 23.6° in 2 ⁇ in the pattern of phase III.
  • FIGS. 29 and 31 Characterization by 1 H NMR, DSC and TGA is shown in FIGS. 29 and 31 .
  • phase III In the 1 H NMR spectrum of phase III the presence of the characteristic signals of P027 indicates that the sample did not decompose. Additionally, in all the spectra measured, the characteristic peak corresponding to poly(ethylene glycol) was observed indicating that phase III is always mixed with this polymer.
  • the 1 H NMR spectrum of poly(ethylene glycol) is represented in FIG. 30 .
  • the DSC analysis of Phase III presents a first sharp endothermic peak with an onset at 56° C. and an enthalpy of 46 J/g corresponding to melting of poly(ethylene glycol).
  • the DSC of pure poly(ethylene glycol) is shown in FIG. 32 . In the range from 150 to 170° C. the DSC shows a double peak, first endothermic and then exothermic, corresponding probably to melting of phase III overlapped with recrystallization to phase I. Finally, an endothermic peak with an onset at 190° C. and an enthalpy of 47 J/g, corresponding to melting followed by decomposition of phase I can be observed.
  • Phase IV form was only generated by polymer induced crystallization. This phase was formed in experiments performed using chloroform as solvent and diisopropyl ether as antisolvent.
  • Phase IV solid was obtained with the following polymers: polyvinyl pyrrolidone (PVP), poly(acrylic acid) (PAA), polypropylene (PPL), poly(styrene-co-divinylbenzene) (PSV), poly(tetrafluoroethylene) (PTF), poly(vinyl alcohol) (PVH), polyacrylamide (PAD) and poly(methyl methacrilate methacrylate) (PMM).
  • PVP polyvinyl pyrrolidone
  • PAA poly(acrylic acid)
  • PPL polypropylene
  • PSV poly(styrene-co-divinylbenzene)
  • PTF poly(tetrafluoroethylene)
  • PVH poly(vinyl alcohol)
  • PAD polyacrylamide
  • PMM poly(methyl me
  • Polymers PVP, PAA, PSV, PVH, PAD and PMM are amorphous and polymers PPL and PTF are crystalline. Only in the sample of phase IV obtained with crystalline PTF, a weak peak of the polymer could be detected in the PXRD pattern.
  • Phase IV form was characterized by PXRD, NMR, DSC and TGA.
  • a representative PXRD pattern for Phase IV is shown in FIG. 35 .
  • FIGS. 36 and 37 Characterization by 1 H NMR, DSC and TGA is shown in FIGS. 36 and 37 .
  • the dioxane solvate crystallizes in form of small sticky crystallites.
  • a representative PXRD pattern of the solvate is shown in FIG. 38 . Characterization by 1 H NMR, DSC, TGA and FTIR is shown in FIGS. 39 to 41 .
  • the DSC analysis of the dioxane solvate presents two overlapped endothermic peaks with onsets at 124° C. and 130° C., probably due to the loss of dioxane, and a third sharp endothermic peak with an onset at 192° C. and an enthalpy of 73 J/g, corresponding to melting followed by decomposition of the product ( FIG. 40 ).
  • the FTIR spectrum characteristic for the dioxane solvate is represented in FIG. 41 and presents intense peaks at 3138, 3055, 2959, 2857, 2660, 2572, 2540, 2444, 1633, 1600, 1556, 1509, 1488, 1446, 1372, 1304, 1289, 1255, 1168, 1118, 1099, 1083, 1039, 933, 872, 861, 819, 771 and 748 cm ⁇ 1 .
  • the chloroform solvate of P027 was obtained by evaporation of a chloroform solution or by crystallization of hot saturated chloroform solutions using the following polymers: poly(ethylene glycol) (PGY), polyvinyl pyrrolidone (PVP), poly (acrylic acid) (PAA), nylon 6/6 (NYL), polypropylene (PPL), poly(tetrafluoroethylene) (PTF), poly(vinyl acetate) (PVA), poly(vinyl alcohol) (PVH), polyacrylamide (PAD) and polysulfone (PLS).
  • PY poly(ethylene glycol)
  • PVP polyvinyl pyrrolidone
  • PAA poly (acrylic acid)
  • NYC nylon 6/6
  • PPL polypropylene
  • PPF poly(tetrafluoroethylene)
  • PVA poly(vinyl acetate)
  • PVH poly(vinyl alcohol)
  • PAD polyacrylamide
  • PLS polysulfone
  • the polymers PGY, PPL and PTF are crystalline and the rest amorphous. No signals of the crystalline polymers could be observed in the PXRD patterns.
  • the chloroform solvate crystallizes in the majority of the cases in form of large crystals which are probably stabilized by the presence of the polymers.
  • a representative PXRD pattern of the solvate is shown in FIG. 42 . Characterization by DSC and TGA is shown in FIG. 43 .
  • the DSC analysis of the chloroform solvate measured with a heating rate of 10° C./min presents a broad endothermic peak with an onset at 67° C. and an enthalpy of 42 J/g, due to the loss of chloroform, and a second sharp endothermic peak with an onset at 194° C. and an enthalpy of 73 J/g, corresponding to melting followed by decomposition of phase I ( FIG. 43 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US15/616,347 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates Active USRE47214E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/616,347 USRE47214E1 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP10382025A EP2361904A1 (en) 2010-02-04 2010-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP10382025 2010-02-04
EP10382226 2010-08-09
EP10382226A EP2426112A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
PCT/EP2011/051630 WO2011095579A1 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
US15/616,347 USRE47214E1 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
US13/577,078 US9051275B2 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Publications (1)

Publication Number Publication Date
USRE47214E1 true USRE47214E1 (en) 2019-01-29

Family

ID=43897079

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/577,078 Ceased US9051275B2 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
US15/616,347 Active USRE47214E1 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/577,078 Ceased US9051275B2 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Country Status (31)

Country Link
US (2) US9051275B2 (es)
EP (1) EP2531177B8 (es)
JP (1) JP5894086B2 (es)
KR (2) KR20120123532A (es)
CN (1) CN102753155B (es)
AR (1) AR080133A1 (es)
AU (1) AU2011212476B2 (es)
BR (1) BR112012018958A8 (es)
CA (1) CA2788024C (es)
CO (1) CO6592093A2 (es)
CY (1) CY1117886T1 (es)
DK (1) DK2531177T3 (es)
EC (1) ECSP12012039A (es)
ES (1) ES2586212T3 (es)
HR (1) HRP20160937T1 (es)
HU (1) HUE029738T2 (es)
IL (1) IL221277A (es)
MA (1) MA34047B1 (es)
ME (1) ME02483B (es)
MX (1) MX339193B (es)
NZ (1) NZ601316A (es)
PL (1) PL2531177T3 (es)
PT (1) PT2531177T (es)
RS (1) RS55046B1 (es)
RU (1) RU2560150C2 (es)
SG (2) SG10201500832PA (es)
SI (1) SI2531177T1 (es)
SM (1) SMT201600264B (es)
TN (1) TN2012000347A1 (es)
TW (1) TWI568729B (es)
WO (1) WO2011095579A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
MA39146A1 (fr) 2013-12-17 2017-11-30 Esteve Labor Dr Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
AR108682A1 (es) 2016-06-06 2018-09-12 Esteve Labor Dr Derivados de pirazol-3-iloxi ligandos del receptor sigma
AR109024A1 (es) 2016-07-12 2018-10-17 Esteve Labor Dr Uso de ligandos del receptor sigma en el dolor post-herpético
WO2018059420A1 (zh) * 2016-09-27 2018-04-05 苏州科睿思制药有限公司 E52862盐酸盐晶型h及其制备方法
WO2019068771A1 (en) 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS
US11535632B2 (en) 2019-10-31 2022-12-27 ESCAPE Bio, Inc. Solid forms of an S1P-receptor modulator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021462A1 (en) 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
US7695199B2 (en) 2006-07-20 2010-04-13 Finisar Corporation Optical subassembly having insertable cylindrical sleeve

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021462A1 (en) 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
US20080125416A1 (en) * 2004-08-27 2008-05-29 Christian Laggner Sigma Receptor Inhibitors
US7696199B2 (en) * 2004-08-27 2010-04-13 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
US7695199B2 (en) 2006-07-20 2010-04-13 Finisar Corporation Optical subassembly having insertable cylindrical sleeve
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Anderson B. D. and Flora K. P., "Preparation of Water-Soluble Compounds Through Salt Formation" The Practice of Medicinal Chemistry, Chapter 34, pp. 739-754.
Berge, S.M. et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 1977, vol. 66, No. 1, pp. 1-19.
Diaz, et al., J. Med. Chem., 2012, 55 (19), 8211-8224. *
Hanner, M. et al., "Purification, molecular cloning, and expression of the mammalian sigma1-binding site" Proceedings of the National Academy of the Sciences, 1996, vol. 93, pp. 8072-8077.
International Search Report issued by the International Searching Authority (ISA/O.E.P.M.) on May 4, 2011 in connection with International Application No. PCT/EP2011/051630.
Lang, M. et al., "The Use of Polymer Heteronuclei for Crystalline Polymorph Selection" Journal of the American Chemical Society, 2002, vol. 124, No. 50, pp. 14634-14335, S1-S2.
Lang, M. et al., "The Use of Polymer Heteronuclei for Crystalline Polymorph Selection", Journal of the American Chemical Society, 2002, vol. 124, No. 50 pp. 14834-14835, S1-S2.
Lee, S. and Hoff, C., "Large-Scale Aspects of Salt Formation: Processing of Intermediates and Final Products", Handbook of Pharmaceutical Salts: Properties, Selection, and Use, 2002, Chapter 8, pp. 191-192, 211-214, Chapter 12, 265-266, 282-283.
Ming L.C., "Screening Polymorphic Forms of Drug Substances by Using Generalized Crystallization Techniques", May 2007 (English language Translation of Abstract).
Price, C.P. et al., "Crystalline Polymorph Selection and Discovery with Polymer Heteronuclei", Journal of the American Chemical Society, 2005, vol. 127, No. 15, pp. 5512-5517, S1-S7.
Quirion, R. et al., "A proposal for the classification of sigma binding sites", Trends in Pharmacological Science, 1992, vol. 13, pp. 85-86.
Rodríguez-Spong, B. et al., "General principles of pharmaceutical solid polymorphism: a supramolecular perspective", Advanced Drug Delivery Reviews, vol. 56 (2004) pp. 241-274.
Snyder, S.H. and Largent, B.L., "Receptor Mechanisms in Antipsychotic Drug Action: Focus on Sigma Receptors", Journal of Neuropsychiatry, 1989, vol. 1, No. 1, pp. 7-15.
Vippagunta, S. R. et al., "Crystalline solids", Advanced Drug Delivery Reviews, vol. 48 (2001) pp. 3-26.
Walker, J.M. et al., "Sigma Receptors: Biology and Function", Pharmacological Reviews, 1990, vol. 42, No. 4, pp. 355-402.

Also Published As

Publication number Publication date
BR112012018958A2 (pt) 2016-04-12
JP2013518857A (ja) 2013-05-23
TW201136923A (en) 2011-11-01
EP2531177B1 (en) 2016-05-11
SI2531177T1 (sl) 2016-10-28
CA2788024A1 (en) 2011-08-11
BR112012018958A8 (pt) 2017-12-19
NZ601316A (en) 2013-12-20
MX339193B (es) 2016-05-16
IL221277A0 (en) 2012-10-31
RU2560150C2 (ru) 2015-08-20
ME02483B (me) 2017-02-20
SMT201600264B (it) 2016-08-31
KR20120123532A (ko) 2012-11-08
CN102753155A (zh) 2012-10-24
SG182628A1 (en) 2012-08-30
MA34047B1 (fr) 2013-03-05
AU2011212476B2 (en) 2016-03-31
ES2586212T3 (es) 2016-10-13
EP2531177A1 (en) 2012-12-12
US9051275B2 (en) 2015-06-09
WO2011095579A1 (en) 2011-08-11
CN102753155B (zh) 2015-11-25
JP5894086B2 (ja) 2016-03-23
US20120316336A1 (en) 2012-12-13
DK2531177T3 (en) 2016-08-22
PL2531177T3 (pl) 2016-11-30
TN2012000347A1 (en) 2014-01-30
RU2012137495A (ru) 2014-03-10
ECSP12012039A (es) 2012-08-31
KR20180063379A (ko) 2018-06-11
HUE029738T2 (en) 2017-04-28
CA2788024C (en) 2018-03-13
IL221277A (en) 2017-06-29
EP2531177B8 (en) 2016-10-12
AU2011212476A1 (en) 2012-08-09
TWI568729B (zh) 2017-02-01
SG10201500832PA (en) 2015-04-29
CY1117886T1 (el) 2017-05-17
AR080133A1 (es) 2012-03-14
MX2012009018A (es) 2012-09-07
CO6592093A2 (es) 2013-01-02
RS55046B1 (sr) 2016-12-30
PT2531177T (pt) 2016-08-17
HRP20160937T1 (hr) 2016-10-07

Similar Documents

Publication Publication Date Title
USRE47214E1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
US9428462B2 (en) 4-[-2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2426112A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2361904A1 (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US20140171462A1 (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
US9174966B2 (en) Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline
US11339164B2 (en) Crystalline form E1 of larotrectinib ethanesulfonate
JP7162964B2 (ja) 化合物の塩及びその結晶形態
TWI752916B (zh) 1-(4-(2-((1-(3,4-二氟苯基)-1h-吡唑-3-基)甲氧基)乙基)哌-1-基)乙酮鹽
US20230064976A1 (en) Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes
EP1956002A1 (en) New tegaserod maleate polymorphs and process for their preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: LABORATORIOS DEL DR. ESTEVE, S.A., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERENGUER MAIMO, RAMON;MEDRANO RUPEREZ, JORGE;BENET BUCHHOLZ, JORDI;AND OTHERS;SIGNING DATES FROM 20120727 TO 20120731;REEL/FRAME:042638/0464

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: ESTEVE PHARMACEUTICALS, S.A., SPAIN

Free format text: CHANGE OF NAME;ASSIGNOR:LABORATORIOS DEL DR. ESTEVE S.A.;REEL/FRAME:063780/0660

Effective date: 20180625